<table>
<thead>
<tr>
<th>Title</th>
<th>Absorption characteristics of model compounds from the small intestinal serosal surface and a comparison with other organ surfaces</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Nishida, Koyo; Kuma, Akiko; Fumoto, Shintaro; Nakashima, Mikiro; Sasaki, Hitoshi; Nakamura, Junzo</td>
</tr>
<tr>
<td>Citation</td>
<td>Journal of Pharmacy and Pharmacology, 57 (8), 1073-1077, 2005</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2005-08</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10069/6678">http://hdl.handle.net/10069/6678</a></td>
</tr>
</tbody>
</table>
Absorption characteristics of model compounds from the small intestinal serosal surface and a comparison with other organ surfaces

Koyo Nishida, Akiko Kuma, Shintaro Fumoto, Mikiro Nakashima, Hitoshi Sasaki and Junzo Nakamura

Department of Clinical Pharmacy, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan

K. Nishida, A. Kuma, S. Fumoto, J. Nakamura

Department of Hospital Pharmacy, Nagasaki University Hospital of Medicine and Dentistry, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan

M. Nakashima, H. Sasaki

Correspondence: K. Nishida, Department of Clinical Pharmacy, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan.

E-mail: koyo-n@net.nagasaki-u.ac.jp

Shortened title: Absorption from small intestinal surface
Abstract

We examined the absorption of phenolsulfonphthalein (PSP) and fluorescein isothiocyanate dextrans (FD-4, MW 4,400; FD-10, MW 9,500; FD-40, MW 40,500) as model compounds through the small intestinal serosal surface. After application to the rat small intestinal serosal surface using a cylindrical diffusion cell, each compound was absorbed at different rates. The absorption ratios in 6 h after PSP, FD-4, FD-10 and FD-40 application were calculated to be 89.2, 34.6, 14.9 and 2.1 % of dose, respectively. Elimination profiles of PSP, FD-4 and FD-10 from the small intestinal serosal surface obeyed first-order kinetics. Moreover, we calculated the apparent permeability coefficient $P_{app}$ for comparison to other organ surfaces. The kidney had the highest absorption efficiency, as shown by having more than 1.5 times significantly higher $P_{app}$ values of PSP, FD-4 and FD-10. Similar to the other organ surfaces, a correlation was observed between the $P_{app}$ of small intestine and the molecular weight of these hydrophilic compounds. In addition, the small intestine is likely to contribute largely to hydrophilic compounds absorption from the peritoneal cavity, judging from absorption clearance $CL_a$ calculated by utilizing the peritoneal organ surface area.
Introduction

The peritoneal cavity is a useful space for intraperitoneal (i.p.) chemotherapy of cancer restricted to the peritoneal cavity, such as peritoneal carcinomatosis and ovarian cancer. The clarification of drug absorption characteristics from the peritoneal cavity would improve peritoneal chemotherapy. Intraperitoneally administered drugs are possibly absorbed from the peritoneum surrounding these peritoneal organs and the abdominal wall. Previously, we reported on drug absorption from the liver surface (Nishida et al 1994), kidney surface (Nishida et al 2004), serosal stomach surface (Mukai et al 1999; Nakamura et al 1999) and serosal caecal surface (Nishida et al 2002) in rats utilizing the diffusion cell, and demonstrated the possibility that the peritoneal organ surface was greatly responsible for drug absorption from the peritoneal cavity. Because the small intestine has the largest peritoneal area (Flessner 1996), its contribution to drug absorption from the peritoneal cavity might be considerable.

In this study, we have examined the absorption of model compounds with different molecular weights after their application to the rat small intestinal serosal surface, by utilizing a diffusion cell. Phenolsulfonphthalein (PSP) and fluorescein isothiocyanate dextrans (FDs) were selected as model compounds because their absorption characteristics from other organ surfaces have been studied (Nishida et al 1995,
1996, 2002, 2004; Mukai et al 1999). Furthermore, we compared the absorption rates among peritoneal organs using quantitative pharmacokinetic parameters.

Materials and Methods

Chemicals

PSP (MW 354) was purchased from Nacalai Tesque, Inc. (Kyoto, Japan). FDs (FD-4, MW 4,400; FD-10, MW 9,500; FD-40, MW 40,500) were obtained from the Sigma Chemical Co. (St Louis, MD, U.S.A.). All other chemicals were of reagent grade.

Animal Experiments

All animal experiments in the present study conformed to the Nagasaki University Guidelines for Animal Experimentation. Male Wistar rats (260 - 290 g) were anaesthetized with sodium pentobarbitone (50 mg kg\(^{-1}\), i.p.) and the body temperatures were kept at 37 °C by a heat lamp during the experiments. The left femoral artery was cannulated with a polyethylene tube (i.d. 0.5 mm, o.d. 0.8 mm, Dural Plastics, Dural, Australia). An incision was made in the middle of the abdomen and the common bile duct was cannulated with a polyethylene tube (i.d. 0.28 mm, o.d. 0.61 mm, Becton Dickinson & Co., Parsippany, NJ, U.S.A.).

The drug solutions were prepared in isotonic phosphate
buffer (pH 7.4) to yield a concentration of 30 mg mL$^{-1}$ and were administered as follows:

A cylindrical diffusion cell (i.d. 4 mm, area 0.13 cm$^2$) was attached to the rat small intestinal serosal surface with the biocompatible glue Aron Alpha (Sankyo Co. Ltd, Tokyo, Japan). The drug solution (1 mg in 0.0334 mL) was added directly into the diffusion cell. The top of the diffusion cell was sealed with aluminum foil to prevent evaporation.

Blood samples (200 μL) were collected at selected times after dosing from the heparinized cannula inserted into the femoral artery over a 6 h period, and were centrifuged at 15,000 rpm for 5 min. Bile samples were collected at appropriate time intervals for 6 h. At 6 h after the application, urine was collected directly from the bladder with a syringe, and the drug solution remaining in the diffusion cell was withdrawn. Certain experiments were carried out up to 0.5, 1, 2, 4 and 6 h after drug application.

**Analysis**

The concentrations of free PSP in the plasma, bile, urine and the solution remaining in the diffusion cell were determined spectrophotometrically at 560 nm after dilution with 1 M NaOH solution, by modifying the method previously described (Hart and Schanker 1966). The total concentrations of free PSP and its metabolite were similarly measured after acid hydrolysis (1 M HCl at 100 °C for 30 min). The concentration of the PSP
metabolite was estimated from the difference between these values.

The concentration of FDs as fluorescence was measured using a spectrophotofluorometer at excitation and emission wavelengths of 489 and 515 nm, respectively, by modifying the method previously described (Kurtzhals et al. 1989).

Analytical validation information is follows. The limits of quantification of PSP, FD-4, FD-10 and FD-40 were 0.010, 0.0027, 0.0010 and 0.0038 µg mL$^{-1}$, respectively. The reproducibility of quantification was guaranteed by inter-day coefficient of variation (PSP, 1.1 %; FD-4, 0.9 %; FD-10, 1.4 %; FD-40, 3.8 %) and intra-day coefficient of variation (PSP, 0.9 %; FD-4, 0.4 %; FD-10, 1.2 %; FD-40, 1.2 %). The linearity of the calibration curve was guaranteed by correlation coefficient ($R^2 > 0.997$). In addition, the validation data were not influenced by the presence of endogenous compounds.

**Statistical Analysis**

In all cases, post-hoc comparisons of the means of individual groups were performed using Tukey's test, following a one-way ANOVA. A significance level of $P < 0.05$ denoted significance in all cases. All values were expressed as the mean value ± standard error (SE) of at least independent different four experiments.
Results

Possibility of drug absorption from the rat small intestinal serosal surface

Figure 1 shows the plasma concentration profiles of PSP, FD-4 and FD-10 after application to the rat small intestinal serosal surface at a dose of 1 mg using the diffusion cell. After absorption from the small intestinal serosal surface, each model compound appeared in the plasma. FD-4 and FD-10 appeared in the plasma at significantly lower concentrations than PSP at each time point (Fig. 1).

Recovery of model compounds in the diffusion cell, bile and urine

Table 1 lists the recovery of model compounds in the diffusion cell, bile and urine 6 h after application to the small intestinal serosal surface at a dose of 1 mg. The absorption ratio (% of dose) in 6 h of model compounds from the small intestinal serosal surface was calculated from the amount recovered from the diffusion cell at 6 h after application. The absorption ratio of PSP (89.2 %) was significantly larger than FD-4 (34.6 %), FD-10 (14.9 %) and FD-40 (2.1 %).

After application to the small intestinal serosal surface, model compounds were excreted into the bile and urine as listed in Table 1. On the other hand, FD-4 and FD-10 absorbed
from the small intestinal serosal surface were mainly excreted into the urine, and their biliary excretion was significantly slight, compared to PSP.

Elimination profiles of PSP, FD-4 and FD-10 from the small intestinal serosal surface

We studied the time courses of PSP, FD-4 and FD-10 remaining in the diffusion cell. The remaining amount (% of dose) of PSP was significantly smaller than FD-4 and FD-10 at each time point. As illustrated in Fig. 2, semi-log plots of the time courses gave straight lines (correlation coefficient $R^2$: 0.973 for PSP, 0.988 for FD-4 and 0.988 for FD-10). This suggests that drug absorption from the rat small intestinal serosal surface proceeds via a first-order process. The absorption rate constants ($k_a$) of PSP, FD-4 and FD-10 were calculated to be $6.10 \times 10^{-3}$, $1.13 \times 10^{-3}$ and $0.45 \times 10^{-3}$ min$^{-1}$, respectively.

Discussion

Because the small intestine occupies about 40 % of the total peritoneal area in rats (Flessner 1996), we considered that its contribution to drug absorption from the peritoneal cavity was remarkable. Flessner reported that absorption from the peritoneal cavity was dependent on the surface area exposed to the solution (Flessner 1996). To obtain information about
drug absorption characteristics after i.p. administration, as a first step, we compared the drug absorption rates from several organ surfaces such as the liver (Nishida et al 1996), kidney (Nishida et al 2004), stomach (Mukai et al 1999) and caecum (Nishida et al 2002), by employing the apparent permeability coefficient $P_{\text{app}}$. $P_{\text{app}}$ was calculated as the absorption clearance per application area, according to the following equation:

$$P_{\text{app}} = \frac{k_a \cdot V_a}{A_{\text{cell}}}$$

Where $V_a$ is the application volume of the drug solution, and $A_{\text{cell}}$ is the application area of the diffusion cell.

Table 2 summarizes the $P_{\text{app}}$ of PSP, FD-4 and FD-10 after application to several organ surfaces. The $P_{\text{app}}$ values of PSP, FD-4 and FD-10 were not significantly changed for small intestine, liver, stomach and caecum. While the kidney had the largest $P_{\text{app}}$ values of PSP, FD-4 and FD-10, as shown by a more than 1.5 times significantly higher $P_{\text{app}}$ value compared to other organ surfaces. These results suggest that the kidney has the highest absorption efficiency for various molecular weight compounds among these organ surfaces.

Flessner measured the mass transfer rates of mannitol to the plasma from fluid in diffusion chambers affixed to the peritoneal surfaces of the rat caecum, liver, stomach and abdominal wall, and determined that the rates of mannitol transport were similar for all four organs (Flessner 1996).
The present result is in agreement with this previous study by Flessner (Flessner 1996) on the similar $P_{\text{app}}$ of the rat caecum, liver and stomach. However, we additionally indicated higher $P_{\text{app}}$ for kidney surface of several model compounds with different molecular weights.

We have clarified that the absorption rates from several organ surfaces were dependent on the molecular weights of the model compounds (Nishida et al 1996, 2002, 2004; Mukai et al 1999). Then, we compared the absorption rates of model compounds with different molecular weights from the small intestinal serosal surfaces. The following equation has been proposed with respect to drug absorption from the gastrointestinal mucosa via passive diffusion (Koizumi et al 1964a-b):

\[
\frac{1}{\sqrt{\text{MW} \cdot P_{\text{app}}}} = A + \frac{B}{P_a} \quad (2)
\]

Where $P_a$ represents the partition coefficient, and constants $A$ and $B$ are the correction factors to $P_a$ and constants for diffusion, respectively.

Because each model compound has a high hydrophilicity (partition coefficient between $n$-octanol and water: < 0.08), $P_a$ as a lipophilic index of each model compound is very small. This might enable us to assume that each $P_a$ value is approximately identical. Then, the right side of Eq. 2 can be transformed as a fixed number. A linear relationship (correlation coefficient $R^2$: 0.997) was observed between the
P<sub>app</sub> values and the 1/√MW values of PSP, FD-4, FD-10 and FD-40 for the small intestinal serosal surface, similar to liver (Nishida et al 1996), kidney (Nishida et al 2004), stomach (Mukai et al 1999) and caecum (Nishida et al 2002). This suggests that these hydrophilic model compounds were absorbed from the rat small intestinal serosal surfaces membranes via simple passive diffusion by the paracellular pathway, similar to other organ surfaces.

Table 2 lists the molecular weights when the P<sub>app</sub> values are 0 (MW limit), calculated by using the intercept of the x-axis (P<sub>app</sub> = 0) on the relationship between the P<sub>app</sub> and 1/√MW. We considered that these values are equivalent to the limits of the molecular weights of drugs which can be absorbed from each organ surface in rats. The limits of the molecular weights were different among the organ surfaces.

Furthermore, we calculated absorption clearance (CL<sub>a</sub>), according to Eq. 3, to estimate the contribution ratio for each organ to absorption from the peritoneal cavity.

\[
CL_a = P_{app} \cdot A_{organ} \quad (3)
\]

CL<sub>a</sub> is the absorption clearance on the peritoneal organ itself from the peritoneal cavity. A<sub>organ</sub> is the peritoneal surface area of an organ, which was previously measured (Flessner 1991). In this case, we assumed that each organ would contribute to drug absorption from the peritoneal cavity according to its proportion of peritoneal surface area in
contact with the peritoneal fluid. As listed in Table 2, \( \text{CL}_{\text{a}} \) values for the small intestine with every model compound were the significantly highest among these organ surfaces, probably by virtue of having the largest peritoneal area in the peritoneal cavity. These results suggest that absorption from the small intestinal serosal surface contributes the most to hydrophilic drug absorption from the peritoneal cavity.

In conclusion, we clarified the absorption characteristics of model compounds with different molecular weights from the rat small intestinal serosal surface by the paracellular pathway. These results should be useful to estimate overall hydrophilic drug absorption rates after i.p. administrations.

Acknowledgments

We wish to thank Yukari Ide and Kayoko Tsuda for their skilled technical assistance. This study was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan, by a Grant-in-Aid from the Uehara Memorial Foundation, by a Grant-in-Aid from the Nakatomi Foundation and by a Grant-in-Aid for Scientific Research from the President of Nagasaki University.
References


compounds with different molecular weights after application to the unilateral kidney surface in rats. Eur. J. Pharm. Biopharm. 58: 705-711
Table 1  Recovery (% of dose) of model compounds 6 h after application to the small intestinal serosal surface at a dose of 1 mg in rats

<table>
<thead>
<tr>
<th>Compound</th>
<th>Diffusion cell (%)</th>
<th>Bile (%)</th>
<th>Urine (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td></td>
<td>10.8 ±1.3</td>
<td>61.9 ±4.0</td>
<td>9.1 ±3.5</td>
</tr>
<tr>
<td>PSP</td>
<td>6</td>
<td></td>
<td>9.1±3.5</td>
</tr>
<tr>
<td>FD-4</td>
<td>65.4 ±1.1</td>
<td>0.9 ±0.1</td>
<td>21.4 ±5.1</td>
</tr>
<tr>
<td>FD-10</td>
<td>85.1 ±0.8</td>
<td>0.4 ±0.1</td>
<td>12.2 ±0.8</td>
</tr>
<tr>
<td>FD-40</td>
<td>97.9 ±0.4</td>
<td>N.D. b</td>
<td>N.D. b</td>
</tr>
</tbody>
</table>

Each value is the mean ± s.e. of at least four experiments.  
a) The biliary and urinary recoveries of PSP represent the total amount of free PSP and its metabolite.  
b) FD-40 could not be detected in the bile and urine.
Table 2  Permeability coefficient (P<sub>app</sub>) and absorption clearance (CL<sub>a</sub>) of model compounds after application to several organ surfaces at a dose of 1 mg in rats

<table>
<thead>
<tr>
<th>Organ</th>
<th>P&lt;sub&gt;app&lt;/sub&gt; (µm min&lt;sup&gt;-1&lt;/sup&gt;)&lt;sup&gt;a&lt;/sup&gt;</th>
<th>A&lt;sub&gt;organ&lt;/sub&gt;&lt;sup&gt;c&lt;/sup&gt;</th>
<th>CL&lt;sub&gt;a&lt;/sub&gt; (µL min&lt;sup&gt;-1&lt;/sup&gt;)&lt;sup&gt;d&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PSP</td>
<td>FD-4</td>
<td>FD-10</td>
</tr>
<tr>
<td>Small intestine</td>
<td>15.9 (6)</td>
<td>2.62 (6)</td>
<td>1.18 (6)</td>
</tr>
<tr>
<td></td>
<td>±0.8</td>
<td>±0.10</td>
<td>±0.07</td>
</tr>
<tr>
<td>Liver</td>
<td>10.9 (4)</td>
<td>2.56 (5)</td>
<td>1.51 (5)</td>
</tr>
<tr>
<td></td>
<td>±1.4</td>
<td>±0.17</td>
<td>±0.18</td>
</tr>
<tr>
<td>Kidney</td>
<td>24.7 (4)</td>
<td>7.11 (4)</td>
<td>3.90 (4)</td>
</tr>
<tr>
<td></td>
<td>±0.8</td>
<td>±0.25</td>
<td>±0.18</td>
</tr>
<tr>
<td>Stomach</td>
<td>12.3 (7)</td>
<td>2.47 (5)</td>
<td>0.76 (6)</td>
</tr>
<tr>
<td></td>
<td>±0.9</td>
<td>±0.21</td>
<td>±0.21</td>
</tr>
<tr>
<td>Caecum</td>
<td>11.2 (8)</td>
<td>2.11 (5)</td>
<td>0.83 (5)</td>
</tr>
<tr>
<td></td>
<td>±0.9</td>
<td>±0.30</td>
<td>±0.13</td>
</tr>
</tbody>
</table>

Each value is the mean ± s.e. of at least four experiments. The number of the experiments were indicated in the parenthesis.

<sup>a</sup> P<sub>app</sub> was calculated by using k<sub>a</sub> according to equation 1. k<sub>a</sub> values were obtained previously: liver (Nishida et al 1995, 1996), kidney (Nishida et al 2004), stomach (Mukai et al 1999), and caecum (Nishida et al 2002).<br>

<sup>b</sup> MW limit was calculated by the intercept of the x-axis on the relationship between P<sub>app</sub> and 1/√MW.<br>

<sup>c</sup> A<sub>organ</sub> (peritoneal absorption area) of rats was reported in the literature (Flessner 1991).<br>

<sup>d</sup> CL<sub>a</sub> was calculated according to equation 3.
Figure 2

![Graph showing remaining amount (% of dose) versus time (min).](image-url)
Figure captions

Figure 1  Plasma concentration profiles of PSP (●), FD-4 (▲) and FD-10 (△) after application to the rat small intestinal serosal surface at a dose of 1 mg. Each point represents the mean ± s.e. of six experiments.

Figure 2  Semi-log plots of the PSP (●), FD-4 (▲) and FD-10 (△) amount remaining in the diffusion cell after application to the rat small intestinal serosal surface at a dose of 1 mg. Each point represents the mean ± s.e. of four experiments. When no error bar is given, s.e. is smaller than the symbol used.